Rejuvenate Biomed Secures EUR 3.2 Million Series A Round to Advance Development of Healthy Aging Products

Rejuvenate Biomed

HEUSDEN-ZOLDER, BELGIUM, March 2, 2021 / — Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round. The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).

The financing included lead investor Vesalius Biocapital III and private non-disclosed investors, as well as existing investors. Additionally, Rejuvenate gratefully acknowledges the ongoing support of Flanders Innovation and Entrepreneurship (VLAIO) in non-dilutive funding. Concurrent with the closing, the company has bolstered its scientific advisory board, which is now composed of Dr. Johan Auwerx, MD, PhD, Dr. Eric Verdin, MD, PhD, Dr. Marco Sandri, MD, PhD, Dr. Bart Braeckman, PhD, Dr. Björn Schumacher, PhD, and Dr. Andrea Maier, MD, PhD. Furthermore, a clinical advisory board has been established which is led by Dr. Jean-Yves Reginster, MD, PhD.

Rejuvenate’s lead candidate RJx-01 is a novel, safe, orally administered, small molecule combination product being developed for sarcopenia, defined by loss of muscle strength, quality and mass. The product was derived from an extensive in silico systems biology program, which mapped existing drugs with curated longevity pathways to create innovative, synergistic and highly effective combinations. RJx-01 has demonstrated strong preclinical evidence in multiple models and, with human safety data on hand for the individual compounds, the company plans to move the program into Phase Ib/IIb clinic trials later this year.

Dr. Ann Beliën, PhD, Founder and CEO of Rejuvenate: “We are very pleased to welcome our lead investor Vesalius Biocapital III as well as the other new investors and wish to thank our existing shareholders for their continued support. Our team is highly driven to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. Using safe products as building blocks to develop innovative combinations such as RJx-01 has created unique opportunities in this field. Our dream of extending people’s health span is becoming a reality.”
Mr. Stéphane Verdood, MBA, MSc, Managing Partner at Vesalius Biocapital III: “Rejuvenate’s data show the potential for RJx-01 to drive our natural capacity to self-restore our cells. The company has a solid scientific and clinical basis coupled with a management team that is rapidly advancing RJx-01 for sarcopenia, and we are excited to be part of the next stage of the company’s growth.”

About Rejuvenate Biomed

Rejuvenate Biomed is an independent Belgian biomedical company established in October 2017 by Ann Beliën, PhD, after nearly two decades of experience with Janssen Pharmaceutical companies of Johnson and Johnson. Rejuvenate aims to increase the healthy years of life, also referred to as a person’s health span, by translating the science behind what keeps cells vital and resilient into human therapeutics. The company is developing safe, proprietary, combination products that delay or prevent the onset of multiple age-related diseases, with a focus on the intersection between fundamental aging mechanisms and chronic conditions.

Rejuvenate Biomed is a resident company of Johnson & Johnson Innovation, JLABS, a premier life sciences incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.

More information at

About Vesalius Biocapital III

Vesalius Biocapital III is a specialist life sciences venture capital fund in line with predecessor funds Vesalius Biocapital I and Vesalius Biocapital II, which have supported life sciences companies since 2007. Vesalius Biocapital I and II contributed to the development of over 20 companies. Vesalius Biocapital III, launched in April 2017, announced a final close with EUR 120 million in commitments. The fund targets later-stage European life science companies in drug development, medtech, diagnostics and digital health. The specialist team is based in Europe and consists of seasoned life sciences professionals with healthcare industry, corporate finance and strategy consulting experience, committed to supporting companies through their growth cycle.

More information at

Ann Van Gysel
Turnstone Communications
+32 9 218 71 97
email us here

Source: EIN Presswire

IntuitiveX Proves Success of Early Stage Life Sciences Commercialization Model

IntuitiveX, a premier life sciences consulting firm and incubator, demonstrates success of its differentiated model for commercializing early stage startups.

SEATTLE, WA, UNITED STATES, March 1, 2021 / — IntuitiveX, a premier life sciences consulting firm and incubator demonstrates the success of its differentiated model for commercializing early stage life sciences companies and has the results to prove it.

After recognizing pain points unique to the life sciences, serial entrepreneur, investor, and physician Dr. Jeffrey Roh, CEO of IntuitiveX, discovered a proprietary methodology and model for catalyzing life sciences startups which has become the cornerstone of IntuitiveX. The methodology and model offer a way to assess the current and future growth potential of early stage life sciences startups while providing a one-stop shop approach to solving these unique growth challenges via consultancy and incubation.

“After repeatedly going through the life sciences maze of innovation as investors, entrepreneurs, and innovators, IntuitiveX has been able to better understand how to efficiently navigate through the complexities of early stage life sciences commercialization. We’ve observed that the more we repeat the maze of testing and validating the model with our clients, the more we iterate on our approach, and the more long-term value we create.” said Dr. Jeffrey Roh, CEO of IntuitiveX.

Since its inception, IntuitiveX has generated millions in value for its investors, portfolio companies, and shareholders and has realized noteworthy portfolio company successes. To name a few, recently AltPep, a Seattle-based biotech startup tackling amyloid protein disorders including Alzheimer’s Disease, raised $23M in series A financing. CarlsMed, leveraging machine learning technologies and prior outcomes data to personalize the treatment for complex adult spinal deformities, has raised $12.6M in funding and recently was granted breakthrough device designation by the FDA. NavLab, a medical IP holding company, generated an IRR of 181% and has a history of creating and selling novel medical device IP assets within the surgical robotics & AI/ML space. Amplify Surgical, developer of a dual expanding interbody fusion system, has surpassed more than 800+ surgical cases and Auctus Surgical, developer of technologies focused on non-fusion scoliosis correction, recently was awarded Best Technology In Spine by OrthopedicThisWeek, a prestigious orthopedic publication. In aggregate, IntuitiveX’s overall portfolio company growth has been staggering, not including the value it has provided for its service clients.

Within a few years, IntuitiveX has been assisting life sciences companies in the following ways: fast-tracking & co-inventing new IP, supporting international commercialization within the U.S., scaling portfolio companies by oversubscribing on seed and Series A rounds across digital health, medtech, pharma, & biotech, opening access into a pipeline of early-stage companies, spearheading FDA servicing, IP commercialization, IP acquisition, business development, joint venture development, mergers, and staffing, and hosting exclusive life sciences events.

“We see great ideas and products ultimately fall short of success because they either do not fully prepare for commercial challenges ahead or they approach hurdles to commercialization in a piecemeal manner. Lack of coordination and integration (e.g. regulatory approval fragmented from IP, product validation devoid of clinical and strategic KOL buy-in, etc.) leads to inefficiencies, gaps, and delays in successful commercialization.” Amy Chen, VP of Client Services.

The IntuitiveX approach assesses key success factors when building a roadmap to commercialization. These vital ingredients are aggregated from their collective experience in launching life science endeavors and prioritized in a balanced approach to business, intellectual property (IP), clinical, and scientific aspects of a strong and de-risked startup company. Utilizing a closed incubation model and a one-stop shop consultancy model, startups are able to get holistic support in the validation, strategy, and execution needed to bring life sciences products to market.

About IntuitiveX
IntuitiveX is a premier life science consulting firm and incubator based in Seattle, Washington that specializes in growing early-stage life science startups and supporting international companies seeking commercialization within the U.S. across medical devices, biotech, Pharma, and digital health. With a team of life science entrepreneurs, physicians, investors, and innovators, we bring a combined 100+ years of experience supporting startups from ideation to commercialization.

Emeka Alozie

Source: EIN Presswire


Wings of Wonder Founder Rebecca Lessard releases Bald Eagle into the blue sky at the top of a snowy hill in Michigan

Wings of Wonder Founder Rebecca Lessard releases a Bald Eagle she rehabilitated

Tribal Leader Joe Mitchell conducts a ceremony in front of a crowd at a Wings of Wonder Bald Eagle release on tribal lands

LTBB of Odawa Indians Tribal Elder and Pipe Carrier Joe Mitchell at a Wings of Wonder Bald Eagle Release on Tribal Lands

A look at the sleek architecture of the Migizi Center in Michigan, designed by tribally-owned Seven Generations

Rendering of the Migizi Aviary and Rehabilitation Center, which will be located north of Harbor Springs in the Northwest part of Michigan’s lower peninsula

Little Traverse Bay Bands and Celebrated Michigan Raptor Expert
Collaborate on First Tribal Eagle Aviary East of the Mississippi River

Migizi, eagles, are highly revered within Odawa culture and are central to many traditional teachings. We are honored to take a leading role in safeguarding and caring for these sacred birds.”

— Doug Craven, LTBB Director of Natural Resources

EMPIRE, MICHIGAN, USA, March 1, 2021 / — Today, Doug Craven, Director of Natural Resources for the Little Traverse Bay Bands (LTBB) of Odawa Indians, and Rebecca Lessard, founder of Wings of Wonder (WOW) raptor rehabilitation center, announced the establishment of the Migizi Aviary and Rehabilitation Center.

Located on LTBB land in the northwestern part of Michigan’s lower peninsula, the center will be the first tribal eagle aviary center east of the Mississippi River, and one of only eight nationwide.

One of the country’s most celebrated raptor rehabilitators, Rebecca Lessard founded and operated WOW in Empire, Michigan, rehabilitating hundreds of eagles and other raptors over 30 years. During that time, Doug Craven and the tribe rescued and transported dozens of eagles and other injured birds of prey to WOW for treatment. Many of these raptors were able to return to tribal lands for release back into the wild.

In recent years, the idea of a tribal raptor center began to incubate as Doug and Rebecca discussed their shared passion for raptors, the importance of eagles to Native American worship and culture, and the need for awareness about the ongoing human impact on birds of prey. They imagined a public raptor center with a rehabilitation hospital and a lifetime home for several non-releasable eagles to educate the public about these majestic birds.

“Migizi, eagles, are highly revered within Odawa culture and are central to many traditional teachings. We take great pride in and are honored to take a leading role in safeguarding and caring for these sacred birds,” said Doug. “We are thrilled to have the opportunity to partner with Rebecca and Wings of Wonder, and to benefit from her matchless knowledge and experience.”

According to Rebecca, the opportunity to work with the LTBB was a blessing. “After 30 years of caring for eagles every day, it was my fondest hope to find a way to pass along my expertise to an organization that could carry this important work into the future,” said Rebecca. “Looking into the eyes of eagles, watching them take flight as they are released back into the wild, it is no wonder that Native Americans revere them. What a joy to be able to help the tribe establish a space of sanctuary and healing for these extraordinary creatures.”

With Doug’s leadership, the LTBB of Odawa Indians have committed to building a state-of-the-art raptor center, hiring tribally-owned Seven Generations (7GAE) of Kalamazoo, Michigan, as architects and engineers. The center will be named “Migizi,” which is a Native American word for eagle. The rehabilitation facility will be named, “The Wings of Wonder Rehabilitation Center,” in honor of Rebecca and her lifelong commitment to saving raptors.

The Migizi Center will cost approximately $600K, which will come from a combination of tribal commitments, grants, and individual contributions. Wings of Wonder, a 501(C)3 non-profit organization that has long supported the rehabilitation of eagles and other raptors, will be the fundraising arm of the project.

“We are asking our loyal contributors and all those who care about the fate of the Bald Eagle to help raise the funds to establish the Migizi center,” said Rebecca. “Every dollar we raise will go directly to work to build pristine enclosures, a clinic for caring for injured raptors, and an aviary that will enable visitors to witness these mighty birds in flight.” Donations can be made at

Once endangered, Bald Eagles are sacred animals in American Indian traditions, culture and religion. They represent honesty, truth, majesty, strength, courage, wisdom, power and freedom — and are believed to have a special connection with the Creator. Many years of federal protection and private rehabilitation have enabled eagles to avoid extinction though they are still at risk from pesticides, hunters, pollution and other environmental hazards.

Joe Mitchell, Little Traverse Bay Bands of Odawa Indians Tribal Elder and Pipe Carrier, said, “The Anishinaabek look to the Eagle as the messenger to the Creator. The Eagle carries our prayers to the Creator. The Eagle lets the Creator know that some of us are trying to live and walk in a Good Way. The Anishinaabek believe that when we see an eagle that we need to respectfully put some tobacco down on Mother Earth to show the Creator that we’re still living in a Good Way and also to thank the eagle for doing his responsibility and showing us that we need to remember our own responsibilities here. The Eagle can see far. Some say that the Eagle Clan people have the ability to see far also, even to the point of seeing people or things as they really are.”

Wendi Strong
Wings of Wonder
+1 210-913-4090
Visit us on social media:

Wings of Wonder Founder Rebecca Lessard Releases a Rehabilitated Bald Eagle Back Into the Wild

Source: EIN Presswire

Vivlion® licenses CRISPR/Cas9 patent portfolio from Broad Institute

Logo of Vivlion, symbolizing CRISPR/Cas technology

Vivlion provides next generation CRISPR/Cas reagents & services

Vivlion Co-Founder & CEO Ivan Dikic

Ivan Dikic, Co-Founder & CEO (Photo by Etienne Doetsch)

The Broad Institute license broadens our license portfolio and enables us to offer our range of R&D CRISPR screening reagents and services to customers worldwide.”

— Ivan Dikic, CEO

FRANKFURT AM MAIN, GERMANY, March 1, 2021 / — Vivlion GmbH today announced the execution of a non-exclusive license agreement with the Broad Institute of MIT and Harvard. The agreement provides Vivlion with access to CRISPR/Cas9 intellectual property from the Broad Institute and its partners.

Vivlion is a Frankfurt-based startup company providing next generation CRISPR/Cas gRNA libraries and screening services for the global R&D market. It holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. “Our 3Cs technology enables the production of high-quality single and dual-combinatorial CRISPR/Cas libraries in any order of diversity. Due to our unique production process, even complex reagents can be produced without compromising on quality”, explained Manuel Kaulich, CSO of Vivlion. The company’s product portfolio includes CRISPR libraries with dual combinations of gRNAs that may be arranged in a multiplexed, random format or in pre-defined, fixed pairs. Whilst multiplex reagents empower gene interaction and synthetic lethality screening, fixed-pair reagents open the field of high-throughput excision genomics in the coding and non-coding genome.

Vivlion was recently featured as “one to watch” in the new Spinoff Prize competition launched by Nature and Merck KGaA Darmstadt, Germany. “The Broad Institute license broadens our license portfolio and enables us to offer our range of R&D CRISPR screening reagents and services to customers worldwide”, added Ivan Đikić, CEO of Vivlion. For more information on Vivlion’s off-the-shelf and customized solutions, visit

About Vivlion GmbH: Vivlion GmbH provides innovative gene editing reagents and screening services for the global R&D market based on the proprietary 3Cs technology developed at Goethe University’s Institute of Biochemistry II. Vivlion is a spin-off of Goethe University Frankfurt am Main, founded in December 2018 by a team of scientists together with Goethe University Frankfurt am Main as a shareholder. Seed funding was secured by a private equity company, gsccb Beteiligungsverwaltung GmbH. For more information on Vivlion’s off-the-shelf and customized solutions, visit

Dr. Kerstin Koch
Vivlion GmbH
+49 69 945158640
Visit us on social media:

Source: EIN Presswire

Bayer AG’s Exposure to Roundup Weedkiller Lawsuits Remains as Trial Lawyers Vow to Continue Fight for Cancer Victims

Dallas law firm representing more than 4,000: Roundup settlement inadequate for thousands sickened by glyphosate-based herbicide 


Bayer is trying to turn its back on thousands who became gravely ill after being exposed to Roundup. We will not let that happen, as a coalition of law firms will continue to press forward to trial.”

— Trial Lawyer Majed Nachawati

DALLAS, TEXAS, UNITED STATES, March 1, 2021 / — Bayer AG (OTCMKTS: BAYRY), the maker of Roundup weedkiller, had hoped a proposed multibillion-dollar partial settlement would end massive legal exposure to pending cancer claims. However, efforts by the company to resolve lawsuits for pennies on the dollar mean one thing — thousands of cancer victims and their lawyers will continue to press forward seeking justice at trial. 

Dallas-based Fears Nachawati Law Firm represents more than 4,000 individual plaintiffs in active litigation against Bayer and continues to investigate new claims on behalf of those sickened after exposure to Roundup.

Rather than a comprehensive resolution framework that would address all pending lawsuits, Bayer has sought to negotiate individually with hundreds of law firms. Trial lawyers opposed to the deal say it’s an attempt to reduce liability and financial exposure and kick the can down the road, all for the sake of pleasing shareholders.

According to published reports, law firms appointed to leadership in the federal multidistrict litigation reached separate agreements that were higher and materially disproportionate to offers for thousands of still-pending lawsuits.

“Bayer is trying to turn its back on thousands who became gravely ill after being exposed to Roundup,” said Dallas attorney Majed Nachawati of the Fears Nachawati Law Firm. “We will not let that happen, as a coalition of law firms will continue to press forward to trial.”

Roundup’s active ingredient, glyphosate, has been linked in published reports to the development of non-Hodgkin’s lymphoma and other forms of cancer. Prior to the proposed partial settlement, juries in three separate trials heard the evidence and returned multimillion-dollar verdicts against Bayer, which acquired the ownership rights to Roundup when it purchased Monsanto in 2018. 

Trial lawyers opposed to the settlement have also voiced criticism of a related lawsuit filed by class-action lawyer Elizabeth Cabraser that would limit the rights of personal injury victims to pursue future damages claims. Bayer continues to sell Roundup, and individuals who fall ill after exposure to the product should be allowed to pursue legal action.

“Bayer’s lawyers have seen what happens when juries hear this evidence,” Mr. Nachawati said. “They think they can get away with this treatment because the pandemic has delayed the ability for cancer victims to go to trial. We will not let that happen without a fight—plain and simple. We will continue to oppose any effort to limit the rights of each individual claimant to get to trial.” 

Dallas-based Fears | Nachawati Law Firm represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation, and individual victims in complex personal injury litigation.  For the past three years, the law firm was ranked number one nationally in product liability filings in federal court. For more information, visit

The MDL case is In re Roundup Products Liability Litigation, case number 3:16-md-02741, in the U.S. District Court for the Northern District of California.

John Raggio
Fears Nachawati
email us here
Visit us on social media:

Source: EIN Presswire

Elevated Demand For Mini C-Arms Devices Boosts Surgical Imaging Arms Market Growth

Surgical Imaging Arms Global Market Report 2021: COVID-19 Growth And Change

Surgical Imaging Arms Global Market Report 2021: COVID-19 Growth And Change

The Business Research Company’s Surgical Imaging Arms Global Market Report 2021: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, March 1, 2021 / — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact:

Read More On The Global Surgical Imaging Arms Market Report:

High demand for mini-C-arms devices is expected to boost market growth during the forecast period. Globally, companies are engaged in the development and manufacturing of novel equipment that assists surgeons in carrying out surgical procedures smoothly and efficiently. The rising demand for mini C-arms devices can be attributed to features such as its miniaturized size, easy adaptability in the operation theatre, and lower price than other types of C-arms. For instance, in January 2018, Hologic, Inc. launched the next generation mini C-arm imaging, the Fluoroscan InSight FD Mini C-Arm. On an intuitive 24-inch HD touchscreen, the device delivers the largest image size and highest image resolution available with the help of features such as high-resolution and low-dose-rate modes. In September 2019, OrthoScan Inc. launched TAU 2020 Mini C-arm which introduces the largest screen on the mini C-arm.
Minimally invasive tests or surgeries incur low costs and saves between $280 million and $340 million in the USA alone by opting for it. With this, the doses can be saved by minimizing shots to enhance work efficiency. Thus, the rising demand for mini C-arms combined with its easy-to-use features is expected to drive the market growth.

TBRC’s surgical imaging systems market report is segmented by product type into G-arm surgical imaging devices, C-arm surgical imaging devices, O-arm surgical imaging devices; by technology into image intensifier C-arms, flat panel detector C-arms; by application into orthopaedic and trauma surgeries, neurosurgeries, cardiovascular surgeries, gastrointestinal surgeries, other applications; by end-user into hospitals and ambulatory surgical centers, academic research institutes.

The global surgical imaging arms market size is expected to grow from $1.08 billion in 2020 to $1.19 billion in 2021 at a compound annual growth rate (CAGR) of 10.41%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.40 billion in 2025 at a CAGR of 4.20%.

Surgical imaging arms industry analysis shows the major players in the market to be GE Healthcare, Hologic Inc., ATON GmbH, Whale Imaging Inc., Siemens Healthcare, Shimadzu Corp., Canon Medical Systems Corporation, Medtronic plc, Ziehm Imaging, Philips Healthcare, Eurocolumbus, GENORAY Co. Ltd., Allengers Medical Systems, Orthoscan, Hitachi.

Surgical Imaging Arms Global Market Report 2021: COVID-19 Growth And Change is one of a series of new reports from The Business Research Company that provides surgical imaging arms market overview, forecast surgical imaging arms market size and growth for the whole market, surgical imaging arms market segments, and geographies, surgical imaging arms market trends, surgical imaging arms market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Surgical Imaging Arms Market Report:

Here Is A List Of Similar Reports By The Business Research Company:
Surgical Equipment Global Market Report 2021: COVID-19 Impact and Recovery to 2030

ENT Surgical Devices And Equipment Global Market Report 2021: COVID 19 Impact and Recovery to 2030

3D Medical Imaging Market Global Report 2020-30: Covid 19 Growth and Change

Nuclear Imaging Devices And Equipment Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Interested to know more about The Business Research Company?
Read more about us at

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
Visit us on social media:

Source: EIN Presswire

Zhimeng Biopharma Announces Global Partner Search for its' Development of a Cure for Chronic Hepatitis B Virus Infection

Image of Hepatitis B Virus, a global infectious disease pathogen

Zhimeng Biopharma is a leading Chinese developer of an anti-Hepatitis B drug

Zhimeng Biopharma is developing ZM-H1505R, an oral Hepatitis B Virus capsid formation inhibitor, for treating patients with chronic hepatitis B virus infection.

ZM-H1505R has the potential to become the leader in curing chronic hepatitis B, a very large and unmet medical need.”

— Dr. Huanming Chen

SHANGHAI, CHINA, March 1, 2021 / — Following a strategic review of its clinical and commercial development options, Zhimeng Biopharma (“Zhimeng”; has appointed The Sage Group (New York and London) to lead the partnering program for its leading drug candidate, ZM-H1505R.

Zhimeng is developing ZM-H1505R, a patented, orally-administered, investigational Hepatitis B Virus (HBV) capsid formation inhibitor, for treating patients with chronic hepatitis B (CHB) virus infection which afflicts 250 million people worldwide.

Zhimeng is a start-up biotech founded in Shanghai, China in 2017 by seasoned pharmaceutical industry veterans (ex- Sanofi, Medicilon, Simcere, Valeant, BioDuro).

In China, the disease burden of HBV is the highest among communicable diseases, and about 10 million people living with chronic HBV will die by 2030. Worldwide, hepatitis B results in 887,000 deaths annually, and chronic infection cases continue to accrue. Of these, about 300,000 deaths are due to liver cancer.

Most of those with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventually develop. Cirrhosis or liver cancer occurs in about 50-60% of those with chronic liver disease.

Currently available therapeutic options for HBV drive a ~$2.5 billion global market.

The hepatitis B virus (HBV) capsid or core protein (Cp) is now being pursued as a target for small-molecule antivirals that enhance the rate and extent of its assembly to yield empty and/or faulty, aberrant capsids. These small molecules represent a promising treatment for suppression of HBV, and are the focus of the development work conducted by Zhimeng.

ZM-H1501R is a novel molecule with a pyrazole structure. It inhibits HBV replication by accelerating the formation of defective virus capsid and is competitively well positioned: the molecule has superior potency and is active against mutant viruses that are resistant to other capsid inhibitors.

Zhimeng has successfully completed a Phase 1A study in the USA and is planning to conduct an 1b study in HBV-infected patients in China in March 2021, leading to a Phase 2 study to be conducted starting in 2022.

Zhimeng is seeking a global partner for ZM-H1501R to facilitate clinical and commercial development of this exciting new drug.
Zhimeng has long lasting and issued patents protecting its discoveries and its pipeline.

Dr. Huanming Chen, CEO of Zhimeng, said “ZM-H1505R has the potential to become the leader in curing chronic hepatitis B, a very large and unmet medical need.”

For more information about Zhimeng Biopharma and partnering opportunities for its pipeline drug candidates, please contact:

Dr. Bill Mason
The Sage Group
The Old Black Barns
Lord’s Lane, Ousden CB8 8TX UK
Tel: +44 (0) 7785 950134


Wayne Pambianchi
The Sage Group Inc.
1802 Route 31 North
#381 Clinton
New Jersey 08809 USA
Phone: +1 908 2306170


Dr. Huanming Chen or Dr. Zhijun Zhang or

About Zhimeng Therapeutics
Shanghai Zhimeng Biopharma Inc. (Zhimeng) is a start-up biotech founded in 2017 by seasoned pharmaceutical industry veterans. Located in the economy-vibrant and resource-rich Zhangjiang High-Tech Park of Shanghai, China, Zhimeng is developing medicines for the treatment of chronic hepatitis B (CHB) and severe neurological diseases with great unmet medical needs.

Realizing the complexity of the pathogenesis of chronic hepatitis HBV infection, Zhimeng has adopted a comprehensive approach to tackle the diseases by directly targeting the hepatitis B virus (HBV) with multiple pronged attacks, as well as through restoring the host immune systems. Zhimeng’s goal is to deliver innovative, most effective, safe and affordable therapies to bring a cure for patients suffering from CHB.

Zhimeng is also actively developing novel small molecule drugs to treat neurological diseases, such as epilepsy, pains and strokes. Zhimeng’s goal is to provide novel and more effective medicines to improve the quality of life of patients with such diseases.


About The Sage Group, Inc.
The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million.

The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.

The range of services offered includes:
• Strategic alliances and licensing/partnering
• M&A, divestment, buy- and sell- side
• Global product and technology acquisition searches
• Strategic assessment and planning
• Due diligence, technology and molecule assessment, valuation
• New ventures, interim management
• Facilitating investment in R&D and/or company equity through introductions, network and brokering

The Sage Group's Principals, each an Executive Director, have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies. These Principals have also held senior level management positions in large multi-national organizations. In addition to their management backgrounds, The Sage Group's Principals also have extensive experience in providing professional management consulting services to healthcare industry clients. All these experiences are being applied by The Sage Group to assist industry participants in these challenging times.


Dr. Bill Mason
The Sage Group
+44 7785 950134
email us here

Source: EIN Presswire

International research collaborations from the new partnership between Kobe University, Japan, and Fourier Intelligence

From top left: Associate Professor Sasithorn Sung-U, Professor Hisafumi Yasuda, Mr Zen Koh, Associate Professor Tomoko Uchida, and Professor Rumi Tanemura. From bottom left: Ms Hayley Lim, Mr Owen Teoh, and Ms Sarah Lim.

From top left: Associate Professor Sasithorn Sung-U, Professor Hisafumi Yasuda, Mr Zen Koh, Associate Professor Tomoko Uchida, and Professor Rumi Tanemura. From bottom left: Ms Hayley Lim, Mr Owen Teoh, and Ms Sarah Lim.

The HandyRehab™ hand exoskeleton on the OTParvos™ digital smartboard.

The HandyRehab™ hand exoskeleton on the OTParvos™ digital smartboard.

Fourier Intelligence’s RehabHub™

Fourier Intelligence’s RehabHub™

This partnership aims to promote advanced rehabilitation technology and integrate group therapy into the clinical setting.

We’re delighted to be able to forge this new partnership with Kobe University to introduce previously research-oriented projects on rehabilitation robotics into clinical settings.”

— Mr Zen Koh, Fourier Intelligence’s Global Hub Chief Executive Officer

SINGAPORE, March 1, 2021 / — Fourier Intelligence has started a new partnership with Kobe University, Japan. This partnership signifies Fourier Intelligence’s global vision in promoting accessibility and adoption of rehabilitation technology. For Kobe University, this is the continuation to integrate education, research, and technology to support clinicians in delivering top-quality rehabilitation services.

The global rehabilitation robots market size was valued at USD 529.8 Million in 2018 and is projected to reach USD 2,617.3 Million by 2026, exhibiting a CAGR of 22.1% during the forecast period. This is according to market research firm Globe Newswire. Demand for rehabilitation robots is expected to be very strong in Japan, given its rapidly greying and shrinking population.

Rehabilitation robots are expected to help the elderly regain their independence of daily living and avoid becoming bed ridden. Robotics can also enable patients to train independently and with minimum clinician intervention. This could be a major incentive for countries facing the dwindling population of working-age people who must care for the increasingly mushrooming number of retirees. By 2035, it is estimated a third of Japan’s population would be aged 65 or older.

Therefore, this partnership comes in timely to address rehabilitation needs for the elderly and neurorehabilitation patient populations. Professor Rumi Tanemura from the Department of Rehabilitation Science would be leading the research efforts for this partnership. The research would focus on Fourier Intelligence’s Upper Limb RehabHub™ series, introducing translational research into the clinical setting. The partnership would focus on the portable finger rehabilitation glove, the HandyRehab™, paired with the digital smartboard, OTParvos™.

“We’re delighted to be able to forge this new partnership with Kobe University, which is one of the highest-ranked universities in Japan,” said Mr Zen Koh, Fourier Intelligence’s Global Hub Chief Executive Officer. “This collaboration aims to introduce previously research-oriented projects on rehabilitation robotics into clinical settings. This will tremendously improve the efficiency of clinical services for clinicians and resulting in better clinical outcomes for patients.”

“We are excited in this partnership with Fourier Intelligence and to join their global research network in introducing advanced rehabilitation technology for Japan’s rehabilitation services,” said Professor Rumi Tanemura. “We believe this is mutually beneficial, as Kobe University trains some of the best therapists in Japan and combining our in-depth clinical knowhow, we can jointly develop technologies that will be highly relevant for our hospitals.”

The Memorandum of Understanding signing event took place virtually on the 24th of February with Professor Hisafumi Yasuda, Dean of the Graduate School of Health Sciences, Kobe University and Mr Zen Koh. The signing was witnessed by Kobe University’s Professor Rumi Tanemura, Associate Professor Tomoko Uchida, and Associate Professor Sasithorn Sung-U from Chiang Mai University. From Fourier Intelligence, Mr Owen Teoh, General Manager, Ms Hayley Lim, Assistant Business Development Director and Ms Sarah Lim, Senior Manager of Clinical Applications and Scientific Research attended the virtual event.

The partnership will focus on efficacy research on upper limb robotics for patients. Ultimately, the partnership will collaborate on multi-centre trials that will involve Fourier Intelligence’s extensive global network of researchers and laboratories.

Kerry GUO (Ms)
Fourier Intelligence
+65 6911 6651
Visit us on social media:

Fourier Intelligence’s HandyRehab™

Source: EIN Presswire